Intertek, which recently acquired Melbourn Scientific, has announced the launch of development, formulation and characterization service for both large and small molecule inhaled and nasal drug products. The acquisition of Melbourn Scientific was announced in July 2013.
The company’s OINDP services include formulation, analytical method development and validation, drug product physical characterisation, Chemistry, Manufacturing and Controls (CMC) support, stability studies, QC release testing, bioanalysis, and extractables and leachables (E&L) testing.
Intertek Melbourn CEO Mark Hammond commented, “The combination of expertise in OINDP development, formulation, bioanalysis, analytical testing and our advanced capabilities for measuring drug/device interaction provides a unique offering to clients working with both small and large molecule medicines.“
Read the Intertek press release.
